When was Samsung Bioepis founded?

Samsung Bioepis was founded in 2012.

Where is Samsung Bioepis located?

Samsung Bioepis is headquartered in Incheon, South Korea.

How many employees does Samsung Bioepis have?

As of Apr 30, 2026, the latest employee count at Samsung Bioepis is 1591.

Is Samsung Bioepis a funded company?

Samsung Bioepis is a funded company, having raised a total of $***** in its 1st and only funding round.

How much is Samsung Bioepis worth?

The last known valuation of Samsung Bioepis was $***** as of Jan 27, 2022.

Where does Samsung Bioepis rank among its competitors?

Samsung Bioepis ranks 26th amongst 1370 active competitors, of which 104 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Johnson & Johnson, which secured $34M in Feb, 2025.

Who are the top competitors of Samsung Bioepis?

Samsung Bioepis' top competitors include AbbVie, Amgen and Gilead. Among them, Johnson & Johnson secured the most recent funding round in February, 2025.

Samsung Bioepis - 2026 Company Profile, Funding, Competitors & Financials

Samsung Bioepis is an acquired company based in Incheon (South Korea), founded in 2012. It operates as a Developer of biosimilar drugs for the treatment of multiple diseases. , with last known valuation of $*****. The company has 1370 active competitors, including 104 funded and 176 that have exited. Its top competitors include companies like AbbVie, Amgen and Gilead.

Company Details

Developer of biosimilar drugs for the treatment of multiple diseases. It is a Joint venture formed by the collaboration of Samsung Biologics and Biogen to develop biosimilars of advanced biologics to treat conditions such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Ontruzant is Samsung Bioepis’ first cancer biosimilar approved by the FDA. It provides biosimilar of Etanercept, Infliximab, Adalimumab, Trastuzumab, Bevacizumab, etc.

Website: samsungbioepis.com
Social
Phone Number: +82 **********
Part Of

Key Metrics

Founded Year

2012

Location

Incheon, South Korea

Stage

Acquired

Last Known Valuation

$***** as on Jan 27, 2022

Investors

Biogen & 1 more

Ranked

26^th among 1370 active competitors

Employee Count

1,591 as on Apr 30, 2026

Investment & Acquisitions

C₂N Diagnostics

Similar Companies

Quell & 83 more

Exit Details

Acquired by Samsung BioLogics (Jan 27, 2022)

View Samsung Bioepis' full profile

Samsung Bioepis is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Samsung Bioepis Co., Ltd CIN: 120111-0601501 , South Korea, Active		$660M (As on Dec 31, 2020)	-	-

Samsung Bioepis got acquired by Samsung BioLogics on Jan 27, 2022 at an acquisition amount of $*****.

Click here to take a look at Samsung Bioepis's acquisition in detail

Samsung Bioepis is a funded company. Samsung Bioepis has 2 institutional investors.

View details of Samsung Bioepis's funding rounds and investors

Samsung Bioepis' employee count trend

Samsung Bioepis has 1,591 employees as of Apr 26. Here is Samsung Bioepis's employee count trend over the years:

Employee count trend for Samsung Bioepis

Uncover Samsung Bioepis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Samsung Bioepis include AbbVie, Amgen and Gilead. Here is the list of Top 10 competitors of Samsung Bioepis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Alcor Fund, Berkshire Hathaway & 8 others	81/100
2nd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Amgen Business Development, Gershon Capital ... & 11 others	81/100
3rd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	BB Biotech, Temasek & 17 others	80/100
4th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Gershon Capital & 11 others	79/100
5th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Alcor Fund, Western Technology Investment ... & 16 others	76/100
6th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
7th	Pfizer 1849, New York City (United States), Public	Provider of pharmaceutical products for multiple disease treatments	-	Alcor Fund, Benson Family Private Equity ... & 16 others	72/100
8th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 7 others	72/100
9th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Gershon Capital & 7 others	71/100
10th	Novartis 1996, Basel (Switzerland), Public	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, MT Capital & 9 others	70/100
26th	Samsung Bioepis 2012, Incheon (South Korea), Acquired	Developer of biosimilar drugs for the treatment of multiple diseases	-	Biogen, Samsung BioLogics	64/100